MedTrace Logo

Ex Vivo Drug Sensitivity Testing and Mutation Profiling

NCT03860376 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2023-05-10

No results posted yet for this study

Summary

This study is a prospective, non-randomized feasibility study. Freshly isolated tumor cells from patients will be screened using state-of-the-art viability assay designed for ex vivo high-throughput drug sensitivity testing (DST). In addition, genetic information will be obtained from cancer and normal (germline) tissue and correlated with drug response. This study will provide the platform for informing treating physician about individualized treatment options. The main outcome of this study will be the proportions of the patients whose treatment was guided by the personalized medicine approach.

Conditions

  • Recurrent Childhood Acute Myeloid Leukemia
  • Recurrent Childhood Acute Lymphoblastic Leukemia
  • Recurrent Childhood Large Cell Lymphoma
  • Refractory Childhood Acute Lymphoblastic Leukemia
  • Refractory Childhood Hodgkin Lymphoma
  • Refractory Childhood Malignant Germ Cell Neoplasm
  • Recurrent Childhood Brain Tumor
  • Recurrent Childhood Brainstem Glioma
  • Recurrent Childhood Rhabdomyosarcoma
  • Recurrent Childhood Soft Tissue Sarcoma
  • Recurrent Childhood Ependymoma
  • Recurrent Childhood Lymphoblastic Lymphoma
  • Recurrent Childhood Gliosarcoma
  • Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Sponsors & Collaborators

  • Nicklaus Children's Hospital f/k/a Miami Children's Hospital

    collaborator OTHER

  • Florida International University

    lead OTHER

Principal Investigators

  • Diana Azzam, PhD · Florida International University

  • Daria Salyakina, PhD · Nicklaus Children's Hospital

Eligibility

Min Age
1 Day
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-21
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03860376 on ClinicalTrials.gov